RAIDD/CRADD Antibody (14G8) [Janelia Fluor® 525]

Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.

Apoptosis is triggered by activation of initiator caspases upon complex-mediated clustering of the inactive zymogen, as occurs in the caspase-9-activating apoptosome complex. Activation of caspase-2 occurs in a complex that contains the death domain-containing protein PIDD, whose expression is induced by p53, and the adaptor protein RAIDD (1). RAIDD has a dual-domain structure similar to that of FADD. It has an NH2-terminal caspase homology domain that interacts with caspase-2 and a COOH-terminal DD that interacts with RIP. RAIDD is constitutively expressed in many tissues and thus could play a role in regulating apoptosis in mammalian cells (2). In metazoan cells there exists inactive polypeptide precursors (zymogens), each composed of a prodomain, which is cleaved to activate the protease, and a large and small catalytic subunit. The coupling of these proteases to signaling pathways is probably mediated by adaptor molecules that contain protein-protein interaction motifs such as the death domain (3).

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Array NBP2-42688JF525

• RAIDD/CRADD Antibodies
• RAIDD/CRADD Lysate
• RAIDD/CRADD Proteins